A class action lawsuit has been filed against Photronics, Inc. and some of its officers, accusing them of making false and misleading statements about the demand for their high-end integrated circuit photomask products. The lawsuit claims that Photronics overstated the strength and sustainability of their product demand due to a significant bottleneck in their design release pipeline, which hindered growth and market opportunities. Investors who purchased Photronics securities between December 10, 2025, and May 27, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of September 4, 2026. The law firm Bronstein, Gewirtz & Grossman, LLC is representing the investors on a contingency fee basis, meaning no upfront costs for investors.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
